Rare Genetic Disease
EB is a group of inherited skin disorders that can cause the skin to blister or tear easily.
Clinical-stage biotechnology
CSA BioTech
Developing CAV-121 for Epidermolysis Bullosa through innate immune system-inspired science.
CSA BioTech's work centers on antimicrobial peptide-inspired biology, including cathelicidins and ceragenin-based therapeutic candidates such as CAV-121.
Wound-Healing Biology
Kill. Clean. Repair.
Disease Focus
Epidermolysis Bullosa
Scientific Basis
Cathelicidin-inspired biology
Development Program
CAV-121
For Patients & Families
Understand Epidermolysis Bullosa
Plain-language information about EB, wound burden, infection risk, and credible external resources.
Read MoreFor Partners & Scientific Visitors
Review the Science and Program
Explore cathelicidin-inspired biology, ceragenins, CAV-121, and the development team.
Read MoreResearch Network Partners
Disease Focus
Focused on Epidermolysis Bullosa
EB is a rare skin-fragility disease where minor friction or trauma can cause painful blistering, skin tearing, and wound formation.
Learn about EBChronic Wound Burden
For severe EB, wounds may become chronic, painful, difficult to heal, and vulnerable to infection.
Infection Risk
Recurring wounds can increase vulnerability to infection and make wound care more complex.
Family Impact
Wound care, dressing changes, pain management, and mobility can create ongoing caregiver burden.
Scientific Approach
A clear path from innate immune biology to CAV-121
CSA BioTech's scientific approach connects EB wound biology with cathelicidins, ceragenins, and CAV-121, an investigational ceragenin-based therapeutic candidate.
01
Innate Immune Biology
The body's first response system helps recognize threats, recruit immune cells, and support tissue repair.
02
Cathelicidins
Antimicrobial peptides such as LL-37 are involved in host defense, immune modulation, and wound-healing biology.
03
Ceragenins
Synthetic small molecules designed to mimic key properties of antimicrobial peptides such as cathelicidins.
04
CAV-121
An investigational ceragenin-based therapeutic candidate being developed for Epidermolysis Bullosa.
Scientific Rationale
Kill. Clean. Repair.
The CAV-121 program is informed by biological pathways associated with innate immune defense, antimicrobial activity, inflammation modulation, and tissue repair.
Kill
Clean
Repair
01
Infection Control
Cathelicidin biology is associated with direct antimicrobial activity.
02
Cell Migration
Wound-healing biology includes keratinocyte movement across the wound bed.
03
Inflammation Modulation
Innate immune signaling can influence inflammatory responses in wounded tissue.
04
Neovascularization
Tissue repair biology includes vascular processes associated with recovery.
05
Tissue Regeneration
Repair pathways are part of the broader rationale for wound closure biology.
Development Program
CAV-121 for Epidermolysis Bullosa
CAV-121 is an investigational ceragenin-based therapeutic candidate being developed for Epidermolysis Bullosa. The program is informed by innate immune biology and the need for new approaches to the chronic wound burden associated with severe EB.
Program Summary
CAV-121
Candidate
- CAV-121
Focus
- Epidermolysis Bullosa
Support
- Cross-functional team
Development Capabilities
Candidate
CAV-121
Disease focus
Epidermolysis Bullosa
Scientific basis
Cathelicidin-inspired biology
Development model
Cross-functional team
Core support
Regulatory, CMC, clinical operations
Status
Investigational therapeutic candidate
Next Steps
Continue with CSA BioTech
Choose the path that matches your role: learn the science, review external resources, or contact the company.